Literature DB >> 16288298

Normal huntingtin function: an alternative approach to Huntington's disease.

Elena Cattaneo1, Chiara Zuccato, Marzia Tartari.   

Abstract

Several neurological diseases are characterized by the altered activity of one or a few ubiquitously expressed cell proteins, but it is not known how these normal proteins turn into harmful executors of selective neuronal cell death. We selected huntingtin in Huntington's disease to explore this question because the dominant inheritance pattern of the disease seems to exclude the possibility that the wild-type protein has a role in the natural history of this condition. However, even in this extreme case, there is considerable evidence that normal huntingtin is important for neuronal function and that the activity of some of its downstream effectors, such as brain-derived neurotrophic factor, is reduced in Huntington's disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16288298     DOI: 10.1038/nrn1806

Source DB:  PubMed          Journal:  Nat Rev Neurosci        ISSN: 1471-003X            Impact factor:   34.870


  226 in total

1.  Wild-type HTT modulates the enzymatic activity of the neuronal palmitoyl transferase HIP14.

Authors:  Kun Huang; Shaun S Sanders; Rujun Kang; Jeffrey B Carroll; Liza Sutton; Junmei Wan; Roshni Singaraja; Fiona B Young; Lili Liu; Alaa El-Husseini; Nicholas G Davis; Michael R Hayden
Journal:  Hum Mol Genet       Date:  2011-06-02       Impact factor: 6.150

Review 2.  Neuroinflammation in Huntington's disease.

Authors:  Thomas Möller
Journal:  J Neural Transm (Vienna)       Date:  2010-06-10       Impact factor: 3.575

3.  Evidence for behavioral benefits of early dietary supplementation with CoEnzymeQ10 in a slowly progressing mouse model of Huntington's disease.

Authors:  Miriam A Hickey; Chunni Zhu; Vera Medvedeva; Nicholas R Franich; Michael S Levine; Marie-Françoise Chesselet
Journal:  Mol Cell Neurosci       Date:  2011-10-20       Impact factor: 4.314

Review 4.  Calcium dysregulation and homeostasis of neural calcium in the molecular mechanisms of neurodegenerative diseases provide multiple targets for neuroprotection.

Authors:  Gregor Zündorf; Georg Reiser
Journal:  Antioxid Redox Signal       Date:  2010-10-06       Impact factor: 8.401

Review 5.  Current Neurogenic and Neuroprotective Strategies to Prevent and Treat Neurodegenerative and Neuropsychiatric Disorders.

Authors:  I M Carvalho; P B Coelho; P C Costa; C S Marques; R S Oliveira; D C Ferreira
Journal:  Neuromolecular Med       Date:  2015-09-15       Impact factor: 3.843

Review 6.  Therapeutic perspectives for the treatment of Huntington's disease: treating the whole body.

Authors:  Bronwen Martin; Erin Golden; Alex Keselman; Matthew Stone; Mark P Mattson; Josephine M Egan; Stuart Maudsley
Journal:  Histol Histopathol       Date:  2008-02       Impact factor: 2.303

7.  Abnormal brain development in child and adolescent carriers of mutant huntingtin.

Authors:  Ellen van der Plas; Douglas R Langbehn; Amy L Conrad; Timothy R Koscik; Alexander Tereshchenko; Eric A Epping; Vincent A Magnotta; Peggy C Nopoulos
Journal:  Neurology       Date:  2019-08-01       Impact factor: 9.910

Review 8.  Animal models of polyglutamine diseases and therapeutic approaches.

Authors:  J Lawrence Marsh; Tamas Lukacsovich; Leslie Michels Thompson
Journal:  J Biol Chem       Date:  2008-10-28       Impact factor: 5.157

9.  Serine 421 regulates mutant huntingtin toxicity and clearance in mice.

Authors:  Ian H Kratter; Hengameh Zahed; Alice Lau; Andrey S Tsvetkov; Aaron C Daub; Kurt F Weiberth; Xiaofeng Gu; Frédéric Saudou; Sandrine Humbert; X William Yang; Alex Osmand; Joan S Steffan; Eliezer Masliah; Steven Finkbeiner
Journal:  J Clin Invest       Date:  2016-08-15       Impact factor: 14.808

10.  Huntington's disease protein contributes to RNA-mediated gene silencing through association with Argonaute and P bodies.

Authors:  Jeffrey N Savas; Anthony Makusky; Søren Ottosen; David Baillat; Florian Then; Dimitri Krainc; Ramin Shiekhattar; Sanford P Markey; Naoko Tanese
Journal:  Proc Natl Acad Sci U S A       Date:  2008-07-31       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.